Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22011137 | 0.88 | OPRL1 (0.34) | MAPTGAADGAT1 | |
| SCHEMBL22010989 | 0.88 | KDM1A (0.32) | MAPTGAA | |
| SCHEMBL22011215 | 0.86 | CYP2C9 (0.36) | MAPTCYP2C9ALDH1A1LMNAMEN1 | |
| SCHEMBL22011006 | 0.85 | CYP2C9 (0.37) | MAPTGAACYP2C9SPHK1ALDH1A1 | |
| SCHEMBL22011213 | 0.84 | FFAR4 (0.37) | — | |
| SCHEMBL22011232 | 0.83 | MAPT (0.32) | MAPTGAAMEN1KMT2A | |
| SCHEMBL2604706 | 0.83 | CYP2C9 (0.36) | MAPTGAACYP2C9SPHK1ALDH1A1 | |
| SCHEMBL8036679 | 0.83 | CYP2C9 (0.36) | MAPTGAACYP2C9SPHK1ALDH1A1 | |
| SCHEMBL22010985 | 0.83 | FFAR4 (0.32) | CYP2C9 | |
| SCHEMBL19985354 | 0.82 | MAPT (0.36) | MAPTGAACYP2C9SPHK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662378-B2 | Compound having fluorodibenzofuran ring, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2020-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10662378-B2 | Compound having fluorodibenzofuran ring, liquid crystal composition and liquid crystal display device | YBX1, ZKSCAN2, RCC1 | MAPT 1234/4885GAA 4418/4885CYP2C9 1213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.